Adaptive Biotechnologies: Current Moat Is Strong, But Value Rides On Long-Term Innovation (Rating Upgrade) [Seeking Alpha]
Adaptive Biotechnologies Corporation (ADPT)
Last adaptive biotechnologies corporation earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adhc.com
Company Research
Source: Seeking Alpha
Per my estimates, ADPT is priced for ~30% annual revenue growth and ~17% FCF margins, so the current valuation offers little margin of safety for investors. clonoSEQ's FDA clearance, broad reimbursement, and market penetration provide a strong moat, though future competition and innovation remain key risks. Rating upgraded to Hold as ADPT successfully transitions post-pandemic, but premium valuation and long-term uncertainties warrant a cautious outlook. JuSun/iStock via Getty Images Introduction My last look at Adaptive Biotechnologies ( NASDAQ: ADPT ) was in September 2024. The company was amid a post-pandemic transition. As revenues from its Immune Medicine (IM) segment, which included a COVID test product, were declining, Adaptive's Minimal Residual Disease (MRD) segment was beginning This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positio
Show less
Read more
Impact Snapshot
Event Time:
ADPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADPT alerts
High impacting Adaptive Biotechnologies Corporation news events
Weekly update
A roundup of the hottest topics
ADPT
News
- Assessing Adaptive Biotechnologies (ADPT) Valuation After a 179% One-Year Rebound and Recent Pullback [Yahoo! Finance]Yahoo! Finance
- Adaptive Biotechnologies (NASDAQ:ADPT) was given a new $21.00 price target on by analysts at Morgan Stanley.MarketBeat
- Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual MeetingGlobeNewswire
- Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why [Yahoo! Finance]Yahoo! Finance
- Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3 [Yahoo! Finance]Yahoo! Finance
ADPT
Earnings
- 11/5/25 - Beat
ADPT
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form 144
- 12/4/25 - Form 144
- ADPT's page on the SEC website